McClellan on PAT
This article was originally published in The Tan Sheet
FDA will publish draft guidance on process analytical technology in September, Commissioner Mark McClellan, MD/PhD, tells Product Quality Research Institute workshop participants on Aug. 5. "I hope you will all have a chance in September...to read our new guidance document that we will be releasing on the use of process analytical technology in making possible innovations in drug manufacturing and quality assurance," he says. The draft guidance is expected to draw from the agency's existing guidance on 21 CFR Part 11 electronic record/electronic signatures (1"The Tan Sheet" Oct. 28, 2002, p. 12)...
You may also be interested in...
FDA plans to draw from existing guidances to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.